<DOC>
	<DOCNO>NCT02951533</DOCNO>
	<brief_summary>The purpose study compare efficacy Guselkumab commercially available active comparator Fumaderm initial/Fumaderm tablet treatment adult participant moderate severe plaque-type psoriasis yet receive systemic therapy .</brief_summary>
	<brief_title>A Study Compare Efficacy Guselkumab Fumaric Acid Esters Treatment Participants With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Have diagnosis plaquetype psoriasis least 6 month first administration study drug Have Psoriasis Area Severity Index ( PASI ) great ( &gt; ) 10 Body Surface Area ( BSA ) &gt; 10 screen baseline Have Dermatology Life Quality Index ( DLQI ) &gt; 10 screen baseline Agree receive live virus live bacterial vaccination study , within 3 month last administration study drug ; information Bacille CalmetteGu√©rin ( BCG ) vaccination , agree receive BCG vaccination study , within 12 month last administration study drug No dipstick detection protein glucose urine . If sign proteins and/or glucose urine test strip , urine sample must analyze centrally . Here , protein glucose level must exceed trace level , example , &lt; = ( + ) ; one retest ( central urine analysis ) allow Has history current sign symptom severe , progressive , uncontrolled liver renal insufficiency , significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , metabolic disturbance Participants nonplaque form psoriasis ( example , erythrodermic , guttate , pustular ) current druginduced psoriasis ( example , new onset psoriasis exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) Known allergy , hypersensitivity , intolerance Guselkumab excipients Is pregnant , breastfeeding , plan become pregnant enrolled study within 12 week last dose study drug Any condition , opinion investigator , participation would best interest participant ( example , compromise wellbeing ) could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>